FacebookTwitterGoogle+RedditEmail

Obama’s Latest FDA Nominee: No Hidden Big Pharma Links, They Are All in Plain Sight

The FDA has been called an arm of the drug industry because of how often it smiles on questionable new drugs and new drug approvals only to issue greater warnings or even withdraw them after the drugs made billions. Remember Vioxx, Baycol, Trovan, Meridia, Seldane, Hismanal and Darvon? They are not around anymore. Why? Remember how popular statins, brand name asthma and psychiatric drugs and GERD drugs were? Once they went off patent, the FDA “discovered” serious side effects and began to list warnings. Sorry about that.

There is a stereotype of backwoods courtroom “justice” in which prosecutors and defense attorneys who appeared to be adversarial leave arm in arm and go for a beer after a judicial decision. No hard feelings. The same collegiality oozes at FDA hearings with FDA staffers seeming to suck up to industry, perhaps for jobs in which they return to squeeze their prior colleagues. (Who remembers former Texas Governor Rick Perry’s chief of staff leaning on Perry to vaccinate all the state’s girls with the Merck vaccine Gardasil after he left for industry?)

FDA advisory panels, whose recommendations the FDA usually follows, are supposed to include “patient representatives” to see that the public’s interests are balanced against Big Pharma consultants. So many doctors and researchers now live on 5 and 6 digit drug company stipends, the FDA actually relaxed conflict of interest rules a few years ago–it could not find enough unlinked doctors!

But the “patient representatives” can be a sham. At one meeting I attended, one “patient representative” was a member of the drug industry-funded National Alliance on Mental Illness (NAMI) which was investigated by Congress for its hidden Pharma income and many consider a front group. The other so-called patient representative” had given keynote speeches at NAMI. So much for transparency.

Because of the huge amount of money to be made from a blockbuster drug like Lipitor—it was the best selling drug in the world—there is a natural tension between drug companies who want to hurry the march to Wall $treet and drug regulators who want to slow it down to protect the public.

That is why the nomination of unapologetic drug industry supporter, Robert M. Califf, for FDA Commissioner is so concerning. A disclosure statement on the website of Duke Clinical Research Institute list 25 drug companies Califf receives “research” funds from including drug giants like Johnson & Johnson, Lilly, Merck, Schering Plough and GSK.

Califf has gone on record that collaboration between industry and regulators is a good thing.  He told NPR, “Many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study.” What?

He is known for defending Vioxx which is reported to have caused at least 50,000 heart attacks and events before its withdrawal. (Merck is said to have known about Vioxx’ cardio effects but marketed the blockbuster drug anyway.)

Califf was instrumental in the Duke drug trial of the blood thinner Xarelto and a cheerleader of the drug despite medical experts’ objections to its approval and 379 subsequent deaths. Duke, where Califf directed clinical research, is still recovering from a major research fraud scandal that resulted in terminated grants, retracted papers and a Sixty Minutes special. It is the least appropriate place from which to choose an FDA Commissioner.

If approved as FDA Commissioner, as many expect, will Califf recuse himself from decisions on the dozens of drugs whose manufacturers pay him? Or will he rule on them anyway? Either way, his nomination is a slap in the face of every honest doctor, researcher and regulator and the public that puts its trust in the FDA. In fact, if the FDA Commissioner is funded by industry, why have an FDA?

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

February 21, 2019
Nick Pemberton
Israel, Venezuela and Nationalism In The Neoliberal Era
Chris Orlet
The Bill and Melinda Gates’ Fair Taxation Scaremongering Tour
Bruce E. Levine
“Heavy Drinking” and the NYT’s Offensive Obit on Herbert Fingarette
Lisi Krall
This Historical Moment Demands Transformation of Our Institutions. The Green New Deal Won’t Do That
Stephanie Savell
Mapping the American War on Terror: Now in 80 Countries
Daniel Warner
New York, New York: a Resounding Victory for New York Over Amazon
Russell Mokhiber
With Monsanto and Glyphosate on the Run AAAS Revokes Award to Scientists Whose Studies Led to Ban on Weedkiller in Sri Lanka and Other Countries
Jesse Jackson
Trump’s Fake National Emergency Moves America Closer to an Autocracy
Alex Campbell
Tracing the Threads in Venezuela: Humanitarian Aid
Jonah Raskin
Mitchel Cohen Takes on Global and Local Goliaths: Profile of a Lifelong Multi-Movement Organizer
Binoy Kampmark
Size Matters: the Demise of the Airbus A380
Elliot Sperber
For Your Children (or: Dead Ahead)
February 20, 2019
Anthony DiMaggio
Withdrawal Pains and Syrian Civil War: An Analysis of U.S. Media Discourse
Charles Pierson
When Saudi Arabia Gets the Bomb
Doug Johnson Hatlem
“Electability” is Real (Unless Married with the Junk Science of Ideological Spectrum Analysis)
Kenneth Surin
The Atlantic Coast Pipeline: Another Boondoggle in Virginia
John Feffer
The Psychology of the Wall
Dean Baker
Modern Monetary Theory and Taxing the Rich
Russell Mokhiber
Citizens Arrested Calling Out Manchin on Rockwool
George Ochenski
Unconstitutional Power Grabs
Michael T. Klare
War With China? It’s Already Under Way
Thomas Knapp
The Real Emergency Isn’t About the Wall, It’s About the Separation of Powers
Manuel García, Jr.
Two Worlds
Daniel Warner
The Martin Ennals and Victorian Prize Winners Contrast with Australia’s Policies against Human Dignity
Norman Solomon
What the Bernie Sanders 2020 Campaign Means for Progressives
Dan Corjescu
2020 Vision: A Strategy of Courage
Matthew Johnson
Why Protest Trump When We Can Impeach Him?
William A. Cohn
Something New and Something Old: a Story Still Being Told
Bill Martin
The Fourth Hypothesis: the Present Juncture of the Trump Clarification and the Watershed Moment on the Washington Mall
February 19, 2019
Richard Falk – Daniel Falcone
Troublesome Possibilities: The Left and Tulsi Gabbard
Patrick Cockburn
She Didn’t Start the Fire: Why Attack the ISIS Bride?
Evaggelos Vallianatos
Literature and Theater During War: Why Euripides Still Matters
Maximilian Werner
The Night of Terror: Wyoming Game and Fish’s Latest Attempt to Close the Book on the Mark Uptain Tragedy
Conn Hallinan
Erdogan is Destined for Another Rebuke in Turkey
Nyla Ali Khan
Politics of Jammu and Kashmir: The Only Viable Way is Forward
Mark Ashwill
On the Outside Looking In: an American in Vietnam
Joyce Nelson
Sir Richard Branson’s Venezuelan-Border PR Stunt
Ron Jacobs
Day of Remembrance and the Music of Anthony Brown        
Cesar Chelala
Women’s Critical Role in Saving the Environment
February 18, 2019
Paul Street
31 Actual National Emergencies
Robert Fisk
What Happened to the Remains of Khashoggi’s Predecessor?
David Mattson
When Grizzly Bears Go Bad: Constructions of Victimhood and Blame
Julian Vigo
USMCA’s Outsourcing of Free Speech to Big Tech
George Wuerthner
How the BLM Serves the West’s Welfare Ranchers
Christopher Fons
The Crimes of Elliot Abrams
FacebookTwitterGoogle+RedditEmail